More than 1 million prescriptions for the COVID-19 antiviral pills Lagevrio and Paxlovid were dispensed between late December 2021 and May 2022, but dispensing rates were lowest in the most socially and economically disadvantaged communities, according to a study released today by the Centers for Disease Control and Prevention. In a separate study of electronic health records from Kaiser Permanente Southern California over the period, fewer than 1% of patients aged 12 and older who received Paxlovid to treat mild-to-moderate COVID-19 had a COVID-19-related hospitalization or emergency department visit in the next five to 15 days. CDC said the studies “highlight the importance of ensuring access to oral antiviral medicine in treating COVID-19, a key strategy in preventing hospitalization and death.”

Related News Articles

Headline
The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment…
Headline
The seven-day average of daily hospitalization due to COVID-19 is up nearly 24% over the previous month, according to data from the Centers for Disease Control…
Headline
The Food & Drug Administration last week revised its Evusheld fact sheet for health care providers, recommending repeat dosing every six months if patients…
Headline
The departments of Health and Human Services and Defense yesterday announced an agreement to purchase at least 105 million doses of a Pfizer omicron-…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration this week…
Headline
The Food and Drug Administration today announced it has revoked the emergency use authorizations for the Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody…